EGFR Positive Lung Cancer UK shared an article by Maise Al Bakir, et al. on X:
“NEW Nature study helps explain why immunotherapy has struggled in EGFR+ lung cancer.
Research shows tumours can change under TKI treatment & immune pressure, losing markers that help the immune system recognise them.”
Clonal driver neoantigen loss under EGFR TKI and immune selection pressures.
Authors: Maise Al Bakir, et al.
